Emerald Advisers LLC Sells 6,062 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Emerald Advisers LLC lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 12.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 41,035 shares of the company’s stock after selling 6,062 shares during the period. Emerald Advisers LLC’s holdings in Teva Pharmaceutical Industries were worth $688,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Migdal Insurance & Financial Holdings Ltd. raised its position in Teva Pharmaceutical Industries by 8.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company’s stock valued at $480,768,000 after purchasing an additional 2,350,000 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in Teva Pharmaceutical Industries by 18.6% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 346,104 shares of the company’s stock worth $5,801,000 after purchasing an additional 54,300 shares in the last quarter. Transcend Capital Advisors LLC grew its stake in Teva Pharmaceutical Industries by 7.6% in the second quarter. Transcend Capital Advisors LLC now owns 13,692 shares of the company’s stock worth $229,000 after purchasing an additional 973 shares in the last quarter. Solstein Capital LLC bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $949,000. Finally, Asset Management One Co. Ltd. boosted its position in Teva Pharmaceutical Industries by 0.8% during the 2nd quarter. Asset Management One Co. Ltd. now owns 432,240 shares of the company’s stock valued at $7,244,000 after acquiring an additional 3,403 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on TEVA shares. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Friday, October 3rd. UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Buy” and a consensus price target of $25.57.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $20.20 on Thursday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market capitalization of $23.16 billion, a PE ratio of -126.22, a P/E/G ratio of 1.09 and a beta of 0.71. The company has a fifty day moving average of $19.21 and a two-hundred day moving average of $17.45. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the prior year, the firm earned $0.61 earnings per share. The business’s quarterly revenue was up .3% compared to the same quarter last year. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.